Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
Small Fiber Neuropathy (SFN) is a challenging condition characterized by damage to the small nerve fibers responsible for pain, temperature, and autonomic functions. Patients often suffer from neuropathic pain and other debilitating symptoms, with limited treatment options addressing the underlying pathology. Recent research, however, points to promising advances in SFN treatment with the introduction of ARA-290 Peptide.
ARA-290 is a synthetic peptide derived from erythropoietin, uniquely designed to selectively activate the innate repair receptor (IRR) without stimulating red blood cell production. This targeted activation is crucial for its therapeutic effects, as the IRR plays a vital role in tissue protection, inflammation reduction, and nerve regeneration. For those exploring small fiber neuropathy treatment options, ARA-290 offers a novel approach that goes beyond symptomatic relief.
Clinical studies investigating ARA-290's impact on SFN have yielded compelling results. Subjects with SFN, including those with diabetic neuropathy, showed significant improvements in neuropathic symptoms. More remarkably, these improvements were correlated with an increase in corneal nerve fiber density (CNFD), an objective measure of small nerve regeneration. This suggests that ARA-290 is not merely masking symptoms but actively promoting the repair of damaged nerve fibers, making ARA-290 nerve regeneration a key area of interest in small fiber neuropathy research updates.
The safety profile of ARA-290 has also been a highlight, with no significant ARA-290-related adverse events reported in trials, making it a well-tolerated option for long-term management. NINGBO INNO PHARMCHEM CO.,LTD. stands as a dedicated ARA-290 peptide manufacturer, ensuring the production of high-quality raw materials that underpin these therapeutic advancements. Their role is pivotal in making this innovative peptide accessible for continued research and clinical application globally.
The potential for ARA-290 to stimulate actual nerve regeneration represents a significant leap forward in the treatment of small fiber neuropathy. As NINGBO INNO PHARMCHEM CO.,LTD. continues to provide ARA-290 as a reliable non-erythropoietic peptide supplier, the medical community can further explore its full therapeutic scope, offering renewed hope for patients suffering from this complex and often intractable condition. This peptide therapy is paving the way for more effective, disease-modifying treatments for neuropathic disorders.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
